Press Release
PathoQuest Announce the Opening of its New U.S. Facility
Press ReleaseThe Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. MarketWayne, PA, and Paris, France – October 4, 2022 – PathoQuest, a leader in the development and provision of Next...
PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of Directors
Rainer Metzger works as a business professional in the Life Science and Pharmaceutical Industry. He has led numerous partnerships for co-development, commercialization, M&A and licensing. Rainer has been in leading positions in precision medicine, initiating and managing partnerships and services for clinical trials, co-development, and commercialization with QIAGEN, ROCHE, DANAHER and MEDICOVER establishing and running business with pharmaceutical companies. Rainer is acting as a board member for a series of Biotech companies in Europe and the US. He holds a Diploma in natural sciences and genetics and a PhD in Biology and Pharmacology from the University of Heidelberg.
PathoQuest Receives GMP Certification for its NGS-based Quality Control Testing Services
We are glad to announce today that PathoQuest has obtained a GMP certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM). PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.
PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital
PathoQuesttoday announced the closing of a financing round up to €15M. This funding leverages the NGS technology in a proprietary approach to assess the viral safety and genetic characterization of biologics. It will support the development of PathoQuest’s US site (Wayne, PA), the expansion of the portfolio of NGS-based quality control (QC) tests and will accelerate its growth and market share worldwide.
PathoQuest, recipient of French Investment Program, expands NGS-based portfolio of quality control tests for biologics
PathoQuest, has been awarded €0.85M from the French Investment Program for the Future (Programme d’Investissement d’Avenir – PIA 4). This financing will enable PathoQuest to expand its range of services with NGS-based quality control (QC) tests for the genetic characterization of biologics at a GMP (Good Manufacturing Practice) grade.
PathoQuest Appoints Eric Cazergue as Chief Financial Officer
Annoucement of the appointment of Eric Cazergue as Chief Financial Officer. Mr. Cazergue’s international career in finance roles within the healthcare industry will be a key asset supporting PathoQuest’s scale-up and global expansion efforts.
Pick another category:
Click here to learn more about PathoQuest’s Biologics Genomic Service for biopharmaceutical companies.
Connect
